Good one Noberto,
The Big D (Diabetes) was mentioned in the Bioshares Report(29 April 2011) as 1st of the rank in "Major Milestones Ahead".
Of interest however is that SCE report(3/3/2011 - Page 7) and valuation of $11.00 does not include diabetes.
Where as Nomura's report(3/5/11 - Page 11) values diabetes application @ $7.70(note: Nomuras Total value of MSB is$17.14 discounted by 61% to $10.45 - Nomura believes Diabetes represents longer term upside for MSB).
Anyway DYOR before making any decision.
Cheers.
good alternative, page-2
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
0.000(0.00%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.08 | $5.380M | 4.893M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 69437 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 19999 | 1 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |